Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cybin Inc
N.CYBN
Alternate Symbol(s):
CYBN
Healthcare
Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary...
deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NEO:CYBN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(87)
•••
Tardis
X
View Profile
View Bullboard History
Post by
Tardis
on Mar 13, 2024 2:07pm
Market Taking The Big Raise Well
Just has to fill that small trading gap. https://ir.cybin.com/investors/news/news-details/2024/Announces-Oversubscribed-Private-Placement-of-U.S.-150-Million/default.aspx Still holding since Small
...more
(31)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Mar 07, 2024 6:58pm
Excellent coverage on CYBN!!
https://youtu.be/uW0vvAkSo18?si=efXVdd8f0bVqOrFV
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 06, 2023 7:30am
New Press Release - Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
- Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary CYB003 deuterated psilocybin analog program -- Cybin’s patent portfolio now includes 39 granted patents and over 170...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 05, 2023 7:30am
New Press Release - Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
- Poster presentations highlight data across Cybin’s CYB003 and deuterated DMT clinical programs, as well as preclinical development programs - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 30, 2023 7:30am
New Press Release - Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
- Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose -- Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating Scale...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 20, 2023 7:31am
New Press Release - Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
- Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer -- Featured key opinion leaders include Dr. Maurizio Fava, M.D., Massachusetts General Hospital and Harvard Medical School; and Dr. Gitte Moos Knudsen, Professor...
read article.
(844)
•••
thorgb1
X
View Profile
View Bullboard History
Post by
thorgb1
on Nov 16, 2023 12:04pm
News: Phase 2 Topline Safety and Efficacy Data for CYB003
Has to be very positive for them to be scheduling an investor briefing..... News here: Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 16, 2023 7:32am
New Press Release - Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
- Company to share topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to...
read article.
(844)
•••
thorgb1
X
View Profile
View Bullboard History
Post by
thorgb1
on Nov 15, 2023 9:10pm
CYBN phase 2 a break through in depression treatment
Article here: https://www.drugdiscoverytrends.com/cybin-interim-phase-2-psilocybin-depression/
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 15, 2023 7:30am
New Press Release - Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 14, 2023 7:16pm
New Press Release - Cybin Reports Second Quarter Financial Results and Recent Business Highlights
- Announced unprecedented positive Phase 2 interim data for CYB003, its proprietary deuterated psilocybin analog, in major depressive disorder -- Announced closing of a unit offering of up to US$64 (C$88.4) million led by one of its largest institutional shareholders -- Strengthened patent...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 14, 2023 1:00pm
New Press Release - Cybin Announces Closing of Offering of Units Led by One of the Company's Largest Institutional Shareholders
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previously...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 10, 2023 8:14am
New Press Release - Canadian Investment Regulatory Organization Trade Resumption - CYBN
TORONTO, Nov. 10, 2023 /CNW/ - Trading resumes in:Company: CYBIN INC.NEO Exchange Symbol: CYBNAll Issues: YesResumption (ET): 8:30 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 10, 2023 8:06am
New Press Release - Canadian Investment Regulatory Organization Trading Halt - CYBN
TORONTO, Nov. 10, 2023 /CNW/ - The following issues have been halted by CIRO:Company: CYBIN INC.NEO Exchange Symbol : CYBNAll Issues: YesReason: Pending NewsHalt Time (ET): 8:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 10, 2023 8:04am
New Press Release - Cybin Announces up to US$64 Million Offering of Units
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce a firm commitment underwritten...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >